UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

Nature communications, 2020-01, Vol.11 (1), p.320-17, Article 320

2020

Volltextzugriff (PDF)

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

Breast cancer research and treatment, 2010-01, Vol.119 (2), p.283-293

2010

Volltextzugriff (PDF)

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

Breast cancer research and treatment, 2012-05, Vol.133 (1), p.237-246

2012

Volltextzugriff (PDF)

Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer

Metallomics, 2019-09, Vol.11 (9), p.1579

2019

Volltextzugriff (PDF)

Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells

Endocrinology (Philadelphia), 2003-03, Vol.144 (3), p.1032-1044

2003

Volltextzugriff (PDF)

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer

PloS one, 2012-07, Vol.7 (7), p.e40466

2012

Volltextzugriff (PDF)

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

Breast cancer research : BCR, 2014-01, Vol.16 (1), p.R12-R12, Article R12

2014

Volltextzugriff (PDF)

The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis

Cellular and molecular life sciences : CMLS, 2021-02, Vol.78 (4), p.1781-1798

2021

Volltextzugriff (PDF)

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (24), p.10238-10246

2008

Volltextzugriff (PDF)

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance

Breast cancer research and treatment, 2008-09, Vol.111 (1), p.79-91

2008

Volltextzugriff (PDF)

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

NPJ breast cancer, 2022-05, Vol.8 (1), p.57-57, Article 57

2022

Volltextzugriff (PDF)

MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer

British journal of cancer, 2019-03, Vol.120 (6), p.621-632

2019

Volltextzugriff (PDF)

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer

Nature structural & molecular biology, 2024-03, Vol.31 (3), p.498

2024

Volltextzugriff (PDF)

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies

International journal of cancer, 2016-01, Vol.138 (1), p.146-159

2016

Volltextzugriff (PDF)

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer

The FEBS journal, 2013-11, Vol.280 (21), p.5237-5257

2013

Volltextzugriff (PDF)

In Vitro Effects on MCF-7 Breast Cancer Cells Of Signal Transduction Inhibitor/Tamoxifen/Eicosapentaenoic Acid Combinations and their Simultaneous Delivery Across Skin

Pharmaceutical research, 2008-11, Vol.25 (11), p.2516-2525

2008

Volltextzugriff (PDF)

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

Breast cancer research : BCR, 2018-08, Vol.20 (1), p.98-98, Article 98

2018

Volltextzugriff (PDF)

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Breast cancer research : BCR, 2013-03, Vol.15 (2), p.R18-R18, Article R18

2013

Volltextzugriff (PDF)

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Breast cancer research : BCR, 2013-10, Vol.15 (5), p.R92-R92, Article R92

2013

Volltextzugriff (PDF)

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer

Nature communications, 2015-07, Vol.6 (1), p.7758-7758, Article 7758

2015

Volltextzugriff (PDF)

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer

Histopathology, 2012-05, Vol.60 (6), p.854-863

2012

Volltextzugriff (PDF)

Growth factor receptor interplay and resistance in cancer

Endocrine-related cancer, 2006-12, Vol.13 (Supplement_1), p.S45-S51

2006

Volltextzugriff (PDF)

erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines

Breast cancer research : BCR, 2011-09, Vol.13 (5), p.R93-R93, Article R93

2011

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Englisch
(105)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer

Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer

In Vitro Effects on MCF-7 Breast Cancer Cells Of Signal Transduction Inhibitor/Tamoxifen/Eicosapentaenoic Acid Combinations and their Simultaneous Delivery Across Skin

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer

Growth factor receptor interplay and resistance in cancer

erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines

Suchergebnisse filtern